Trial reportThe Journal of allergy and clinical immunology2018
Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications.
Trial report in The Journal of allergy and clinical immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.The European respiratory journal · 2026Review
- The bronchoalveolar proteome changes in obesity.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Immunometabolic programming of macrophages in asthma pathogenesis and therapy.Frontiers in physiology · 2025Review
- Surfactant Protein A Inhibits Human Rhinovirus C Binding and Infection of Airway Epithelial Cells from Pediatric Asthma.Viruses · 2024Article
- Asthma Pathogenesis: Phenotypes, Therapies, and Gaps: Summary of the Aspen Lung Conference 2023.American journal of respiratory cell and molecular biology · 2024Review
- Cooperation of immune regulators Tollip and surfactant protein A inhibits influenza A virus infection in mice.Respiratory research · 2024Article
- Bibliometric Insights into Research Hotspots and Trends in Obesity and Asthma from 2013 to 2023.Obesity facts · 2024Article
- Eosinophil-Epithelial Cell Interactions in Asthma.International archives of allergy and immunology · 2024Review
- SURFACTANT PROTEIN A: AN INNATE IMMUNE MODULATOR AND THERAPEUTIC IN ASTHMA.Transactions of the American Clinical and Climatological Association · 2024Review
- The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.International journal of molecular sciences · 2023Review
- Obesity-related asthma and its relationship with microbiota.Frontiers in cellular and infection microbiology · 2023Review
- Novel potential treatable traits in asthma: Where is the research taking us?The journal of allergy and clinical immunology. Global · 2022Review
- Clinical Characteristics and Management Strategies for Adult Obese Asthma Patients.Journal of asthma and allergy · 2022Review
- Associations Between Asthma and Polycystic Ovary Syndrome: Current Perspectives.Frontiers in endocrinology · 2022Review
- Small Peptide Derivatives Within the Carbohydrate Recognition Domain of SP-A2 Modulate Asthma Outcomes in Mouse Models and Human Cells.Frontiers in immunology · 2022Article
- Myeloid-associated differentiation marker is a novel SP-A-associated transmembrane protein whose expression on airway epithelial cells correlates with asthma severity.Scientific reports · 2021Article
- The Role of Obesity in the Immunopathogenesis of COVID-19 Respiratory Disease and Critical Illness.American journal of respiratory cell and molecular biology · 2021Review
- Childhood Obesity and Respiratory Diseases: Which Link?Children (Basel, Switzerland) · 2021Review
- Regulation of Immune Responses by Nonhematopoietic Cells in Asthma.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- From Allergy to Cancer-Clinical Usefulness of Eotaxins.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundEosinophils are prominent in some patients with asthma and are increased in the submucosa in a subgroup of obese patients with asthma (OAs). Surfactant protein A (SP-A) modulates host responses to infectious and environmental insults.
objectiveWe sought to determine whether SP-A levels are altered in OAs compared with a control group and to determine the implications of these alterations in SP-A levels in asthmatic patients.
methodsBronchoalveolar lavage fluid from 23 lean, 12 overweight, and 20 obese subjects were examined for SP-A. Mouse tracheal epithelial cells grown at an air-liquid interface were used for mechanistic studies. SP-A
resultsSignificantly less SP-A (P = .002) was detected in samples from OAs compared with those from control subjects. A univariable regression model found SP-A levels were significantly negatively correlated with body mass index (r = -0.33, P = .014), whereas multivariable modeling demonstrated that the correlation depended both on asthma status (P = .017) and the interaction of asthma and body mass index (P = .008). Addition of exogenous TNF-α to mouse tracheal epithelial cells was sufficient to attenuate SP-A and eotaxin secretion. Allergen-challenged SP-A
conclusionsSP-A functions as an important mediator in resolving tissue and lavage fluid eosinophilia in allergic mouse models. Decreased levels of SP-A in OAs, which could be due to increased local TNF-α levels, might lead to impaired eosinophil resolution and could contribute to the eosinophilic asthma phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.